CLAIMS

1. A free-flowing solid pharmaceutical formulation comprising (1) lyophilizing granules comprising one or more active ingredients and (2) a blend composition comprising sorbitol and liquid paraffin, wherein

the blend composition comprises 95% to 99.9% by weight of sorbitol, 0.1% to 5% by weight of liquid paraffin, and 0% to 4% by weight of citric acid, and

the formulation comprises 0.01% to 30% by weight of active ingredient(s), 70% to 99.99% by weight of the blend composition, and 0% to 30% by weight of the other pharmaceutically acceptable excipients.

~~2. The formulation according to claim 1 wherein the blend composition further comprises citric acid.~~

~~3. The formulation according to claim 1 or 2 comprising 0.01% to 30% by weight of active ingredient(s), 70% to 99.99% by weight of the blend composition, and 0% to 30% by weight of other pharmaceutically acceptable excipients.~~

~~4.~~2. The formulation according to claim ~~3~~1 comprising 0.1% to 28% by weight of active ingredient(s), 72% to 99.9% by weight of the blend composition, and 5% to 30% by weight of one or more other pharmaceutically acceptable excipients.

~~5. The formulation according to any one of claims 1 to 4 wherein the blend composition comprises 95 to 99.9% by weight of sorbitol, 0.1% to 5% by weight of liquid paraffin, and 0 to 4% by weight of citric acid.~~

~~6.~~3. The formulation according to claim 1 or ~~2~~5 wherein the blend composition comprises 96% to 99.5% by weight of sorbitol, 0.5% to 4% by weight of liquid paraffin, and 0.5% to 2% by weight of citric acid.

~~7.~~4. The formulation according to claim ~~5~~1 or 2 wherein the blend composition consists of 95% to 99.9% by weight of sorbitol, 0.1% to 5% by weight of liquid paraffin, and 0% to 4% by weight of citric acid.

~~8.~~5. The formulation according to claim ~~7~~4 wherein the blend composition consists of 96% to 99.5% by weight of sorbitol, 0.5% to 4% by weight of liquid paraffin, and 0.5% to 2% by weight of citric acid.

~~9.~~6. The formulation according to any one of claims 1 to 5~~8~~ wherein the active ingredient is selected from the group consisting of desloratadine, montelukast, solifenacin, silodosin, sildenafil and pharmaceutically acceptable salts ~~there~~of the aforementioned active ingredients, and desmopressin and desmopressin acetate.

~~10.~~7. The formulation according to any one of claims 1 to 5~~8~~ wherein the active ingredient is desloratadine, or a pharmaceutically acceptable salt thereof.

8. The formulation according to any one of claims 1 to 5 wherein the active ingredient is montelukast or a pharmaceutically acceptable salt thereof.

9. The formulation according to any one of claims 1 to 5 wherein the active ingredient is silodosin or a pharmaceutically acceptable salt thereof.

~~11.~~10. The formulation according to any one of claims 1 to ~~8~~5 wherein the active ingredient is sildenafil or a pharmaceutically acceptable salt thereof.

~~12.~~11. The formulation according to any one of claims 1 to 8 wherein the active ingredient is solifenacin or a pharmaceutically acceptable salt thereof.

12. The formulation according to any one of claims 1 to 5 wherein the active ingredient is desmopressin or desmopressin acetate.

13. A package containing the formulation according to any one of the preceding claims.

14. The package according to claim 13 selected from the group consisting of a sachet and a stick pack.

~~15. A solid blend comprising sorbitol and liquid paraffin for use in the manufacture of a pharmaceutical formulation comprising one or more active ingredients.~~

~~16. The solid blend according to claim 15 which further comprises citric acid.~~

~~17. The solid blend according to claim 15 or 16 comprising 95 to 99.9% by weight of sorbitol, 0.1% to 5% by weight of liquid paraffin, and 0 to 4% by weight of citric acid.~~

~~18. The solid blend according to claim 17 consisting of 95 to 99.9% by weight of sorbitol, 0.1% to 5% by weight of liquid paraffin, and 0 to 4% by weight of citric acid.~~

~~19. The solid blend according to any one of claims 15 to 18 wherein the active ingredient is selected from the group consisting of desloratadine, montelukast, solifenacin, silodosin, sildenafil and pharmaceutically acceptable salts thereof.~~

~~20. The solid blend according to any one of claims 15 to 18 wherein the active ingredient is desloratadine.~~

~~21. The formulation according to any one of claims 15 to 18 wherein the active ingredient is sildenafil.~~

~~22. The formulation according to any one of claims 15 to 18 wherein the active ingredient is solifenacin.~~

~~23.~~15. A process for the manufacture of a pharmaceutical formulation as defined in any one of claims 1 to 12 comprising:

(a) forming a lyophilized powder by subliming the solvent from a preparation comprising one or more active ingredients and ~~the~~ a solvent;

(b) forming a blend composition comprising or consisting of sorbitol, liquid paraffin and optionally citric acid;

(c) mixing the blend composition obtained in step (b) with the lyophilized powder obtained in step (a), wherein the blend composition comprises or consists of 95% to 99.9% by weight of sorbitol, 0.1% to 5% by weight of liquid paraffin, and 0% to 4% by weight of citric acid, and the formulation comprises 0.01% to 30% by weight of active ingredient(s), 70% to 99.99% by weight of the blend composition, and 0% to 30% by weight of other pharmaceutically acceptable excipients.